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Abstract Over 400 human proteases documented in secondary
databases can already be delineated in genomic sequence. A
Genome Ontology annotation of 30 585 sequences in the
provisional human proteome set recognises 498 proteases, i.e.
1.6%. Homology searches against finished sequence and
comparisons between mouse and zebrafish are likely to increase
this total. However, the data already indicate that the
mechanistic class, sequence family and domain distribution of
the genomic complement of proteases is unlikely to shift
significantly from that already observed in the transcript data.
Genomically derived novel sequences will require bioinformatic
analysis and biochemical verification. The increasing availability
of annotated genomic data will enable studies of splice variants,
transcriptional control, polymorphisms, pseudogenes, inactive
homologues and evolution. Comparative work on complete
human protease families should produce a more integrated
picture of their biochemistry and physiology. Genomic data will
also lead to the identification of new protease involvement in
disease processes and their evaluation as drug targets. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Human genome data will impact protease research in ¢ve
main areas. The ¢rst is the ability to study, in silico, in vitro
and in vivo all paralogous members of a human protease
family. The study of individual proteases often leaves ques-
tions as to the extent of unique or partitioned biochemical
roles as opposed to functional redundancy. Examples of par-
allel studies include the expression analysis of all 15 human
kallikrein sequences on 19q13 [1], comparisons between
BACE on 11q22.2 and BACE2 on 21q22.3 [2,3], or the two
angiotensin-converting enzymes, ACE1 from 17q23 and
ACE2 from Xp22 [4]. With the caveat of the small remaining
gaps, the genomic complement of these three families is likely
to be complete. The second impact will be the opportunity to
study species orthologues, not only for the similarities and
di¡erences in physiological context between human, mouse
and ¢sh but also, in some cases, conserved biochemical func-
tion compared to ancestral homologues in yeast, worm or £y.
The same examples can be used here; mice have a larger
number of kallikrein genes, at least some of which may not
have true human orthologues [1]. BACE1 and BACE2 have
only single rat and mouse orthologues but share at least one
common ancestor in ¢sh [5]. Similarly ACE1 and ACE2 each
have rodent orthologues but ACE-like homologues can be
traced back to the £y [6].
The third impact will be in the study of gene structure, such
as exon/intron organisation, splice variants, transcriptional
regulation, mutations, polymorphisms and evolutionary his-
tory. Again, these can include comparisons between human,
mouse and ¢sh. The fourth area will be investigating the roles
of the ancillary functional sequence units, such as signal pep-
tides, propeptides, transmembrane helices, lipid anchor re-
gions or interaction domains that are found in association
with catalytic modules. The multiplicity and permutations of
these are a de¢ning charateristic of vertebrate proteases. Last
but not least, the availability of the predicted proteome will
lead to the identi¢cation of new biochemically important pro-
tease substrates and/or endogenous modulators of their activ-
ity.
2. Genomic and transcript data sources
Monitoring the avalanche of data entering the GenBank/
EMBL divisions for new protease sequences is a daunting
task. However, the biological community is increasingly well
provided with secondary databases that extract and curate
subsets from the primary data. Many of these have utility
for the study of proteases but only a few personal favourites
can be described here. Top of this list is the MEROPS pro-
tease database that provides a regularly updated compendium
of all proteases extracted from the primary databases [7]. As
well as grouping these at the species and sequence family level
the database also provides the internationally accepted mech-
anism and alignment-based protease classi¢cation system that
will be used in this article. The RefSeq resource maintains a
non-redundant set of human mRNAs, which are mapped onto
genomic sequence via LocusLink [8]. The SwissProt/TrEMBL
(SP-TR) protein database includes a non-redundant set of
human sequences [9]. InterPro is a comprehensive protein
family and domain database, which provides automated an-
notation for all of SP-TR including the human proteome set
[10]. Ensembl is a major project for providing homology-sup-
ported predicted gene products from a ‘golden path’ of as-
sembled human genome data [11]. This is regularly updated
for viewing gene models and many other features extracted
from the sequence data, including InterPro matches for the
predicted proteins.
So how do these data sources relate to each other for as-
sessing proteases in a genomic context? Most human entries
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in MEROPS can be linked to a SP-TR protein sequence and a
RefSeq mRNA. The protease classi¢cations in MEROPS
largely correspond to those derived by InterPro. However,
some family divisions made on the basis of manually aligned
catalytic regions in MEROPS, may be merged as a conse-
quence of the use of automated scoring thresholds against
the domain databases underpinning InterPro. The unique ad-
vantage of the latter is the identi¢cation and graphical depic-
tion of all the known domains, in addition to the catalytic
modules (see Fig. 1) [10,12]. For visualising genomic context,
most of the MEROPS or InterPro entries can now be ¢ne-
mapped (i.e. unequivocally aligned at the exon level) onto
genomic sequence, via either LocusLink or Ensembl. The lat-
ter includes those proteases not represented as mRNA entries
in RefSeq but have enough similarity matches to known se-
quences to support a predicted gene model. An example of
the progress already made in genome annotation is given in
Fig. 1.
3. Genomic and transcript protease numbers (as of
March, 2001)
Although the gene product inventory is some way from
completion, the recent human genome paper included the ¢rst
compilation of an integrated protein index of 31 778 protein
sequences [11]. An updated set of 30 585 sequences was re-
leased on the European Bioinformatics Institute website.
This includes 15 691 SP-TR proteins and an additional
14 894 proteins predicted by Ensembl. The entire set was an-
alysed by InterPro for domain and protein family composi-
tion. The non-redundant mRNA total in RefSeq now stands
at 15 752. This means that approximately half of all human
proteins are already represented as full-length coding sequen-
ces.
De¢ning the number of proteases in silico, from transcript
or genomic data, as well as detecting their possible evolution-
ary relationships, requires the application of scoring thresh-
olds to the results of searching or alignment algorithms.
Although the practical choice of these methods lies outside
the scope of this review, it is important to note that the sec-
ondary databases interrogated for this article, MEROPS, In-
terPro and Ensembl, assign both domain and family homol-
ogy conservatively. For such large-scale operations there are
many good reasons to stay out of the ‘twilight zone’. One
advantage for proteases, is that the inferred biochemical prop-
erties, automatically or manually transferred during annota-
tion of a new sequence, should be reliably linked to the small
(and shrinking in relative numbers) subset of proteins whose
catalytic activity has been experimentally demonstrated. In
expert hands, the targeted use of low-similarity thresholds
can certainly extend the homology identi¢cation envelope to
include, for example, a newly extended superfamily of pre-
dicted cysteine proteases that includes ¢ve Caenorhabditis
elegans and four human paralogues [13].
In terms of absolute numbers, the MEROPS database cur-
rently lists 405 human sequences. This corresponds to 2.9% of
known human proteins but only 1.3% of the 30 585 genome
set. A preliminary Genome Ontology annotation of this set
classi¢ed 498 proteases i.e. 1.6% (see www.ebi.ac.uk/pro-
teome/). The InterPro annotations of the Ensembl release in-
clude 297 proteases in the 25 790 con¢rmed gene set i.e. about
1.2%. These relative numbers are signi¢cantly below the 1.8%
estimate made recently which was largely based on model
organism data [14]. However, there are technical reasons
why these initial genome-wide automated annotations may
underestimate the protease total. Between now and the com-
pletion of the human data, the increase in mammalian mRNA
and EST coverage, together with exon comparisons between
human, mouse and zebra¢sh, are likely to increase the pro-
tease total. Given that the probability of a human sequence
being cloned is, to very rough approximation, proportional to
its mRNA abundance, it can be speculated that those new
genome-derived proteases con¢rmed as real transcripts may
be low-abundance or and/or tissue-speci¢c gene products.
4. Mechanism, sequence family, and domain distribution
Although the human sequences in MEROPS approximately
doubled between 1998 and 2000, there was relatively little
shift in the mechanistic class distribution. These currently
stand at 3% aspartic, 23% cysteine, 36% metallo, and 32%
serine. The four largest families, the S1 trypsin^serine pro-
teases, the M12 ADAM metalloproteases, the C12/C19 ubiq-
uitin-speci¢c proteases and M10 matrix metalloproteases,
have undergone major expansions over this period. These
transcript-derived totals stand at 101, 35, 31, and 24 members
respectively. However, comparison with InterPro annotation
of the proteome set, including for example 118 trypsin pro-
teases, indicates that the expansion of these families by con-
tributions from new genomic predictions, is modest. This sug-
gests that the ¢nal protease set will have a broadly similar
family composition to those already represented in transcript
data. The human genome paper also reported that the trypsin-
like (S1) serine proteases are associated with 18 other domains
[11]. Although none of these were novel, it seems likely that
expert analysis of the type recently reported for the protease-
associated domain may reveal new combinations [15]. For
those domains that are annotated the InterPro query tools
enable interrogation of their species and sequence family com-
binations [10,12].
5. Inactive homologues and pseudogenes
The MEROPS database has assigned 12% of the protease
sequences as inactive homologues using the criteria of residue
substitutions within critical active-site regions. However, it
should be borne in mind that, from the vast number of pro-
tease homologues predicted from nucleic acid sequences, only
a minority have been experimentally proven to be catalytically
active. In fact only 18% of the 1634 protease families across
all organisms currently in MEROPS have an Enzyme Com-
mission number for one of their members. Nearly all of the
major protease families include at least one inactive pa-
ralogue. The ADAM (M12) family has the largest propor-
tional representation of 34%. Interestingly, these are at di¡er-
ent chromosomal locations. Any new inactive homologues
revealed in genomic data are worthy of biochemical investi-
gation because they can have the same functional set of an-
cillary domains as their catalytically active paralogues.
Pseudogenes in genomic DNA result from reverse transcrip-
tion from a mRNA transcript (processed pseudogenes) or
from gene duplication and subsequent degradation (non-pro-
cessed pseudogenes). Although these are considered ‘dead’,
the RefSeq human mRNA entries include over 1000 tran-
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scribed pseudogenes. Examples of protease pseudogenes have
recently been reported within the kallikrein and tryptase gene
clusters on 19q13 and 16p13 respectively [1,16]. An example
of an actively transcribed protease pseudogene is the (pro)
napsin-B gene [17]. The mRNA is found exclusively in cells
related to the immune system but lacks an in-frame stop
codon and contains a number of polymorphisms, one of
which replaces a catalytically crucial Gly residue with an
Arg. It will require the data quality level of ¢nished genomic
sequence before such subtle di¡erences between translated and
non-translated proteases can be discerned with con¢dence in
silico.
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6. Alternative splicing and polyadenylation
Alternative transcript-splicing is predicted to a¡ect at least
35% of all human gene products and the extent of alternative
polyadenylation positions within the 3P terminal exons re-
mains unknown [18]. Both processes introduce additional
layers of complexity into protease biology. For example, all
the numbers quoted in Section 4, which were implicitly one
gene^one mRNA^one protein, have to be expanded by 40%
to give a more plausible picture of transcript permutations,
without even considering di¡erential polyadenylation. To use
a long-standing example it is only recently that a physiological
basis has been proposed to explain the expression of the en-
zymatically equivalent somatic and germinal isoforms of ACE
[19]. Two cases have recently been described where tissue-spe-
ci¢c removal of introns near active sites can give rise to cata-
lytically inactive proteins but where ancillary interaction or
anchoring domains may still be active. The ¢rst of these is a
novel BACE mRNA lacking a 44-amino acid region from
exon 3, located between the two catalytic aspartyl residues
[20]. This is expressed as a pancreas-speci¢c splice variant
but is absent in brain. These ¢ndings can explain the previ-
ously observed paradox of high BACE transcription in pan-
creas with very low enzymatic activity but raises the question
of what functional role this splice variant might have. To add
to the transcript complexity of BACE there are at least three
forms observed in multiple tissue Northern blots and public
mRNA sequences that arise from di¡erent polyadenlylation
positions in the 3P UTR rather than alternative exon usage
[21].
The second case is HtrA2, a protein related to the bacterial
heat-shock proteases, consisting of eight exons on 2p13.1 [22].
There are two reports of alternatively spliced forms [22,23].
One paper characterises the form that is expressed predomi-
nantly in the kidney, colon and thyroid, but lacks peptide
sequence encoded by exons 3 and 7 [23]. The absence of
exon 7 leads to a protein with a modi¢ed PDZ domain unable
to interact with a known partner, the Mxi2 protein. Splicing-
out exon 3 leads to a protein with no detectable protease
activity. The authors suggest that this splice variant may
have a unique role in these tissues. The genomic annotation
view of the HtrA2 locus (see Fig. 1) indicates the situation
may be even more complex. No less than four alternative
transcripts have been deposited as mRNA entries, including
additional forms that are lacking either exon 3 or exon 7.
Although both the extent and functional signi¢cance of alter-
native splicing or polyadenylation events remains unknown, at
least the availability of all potential exonic data in the genome
sequence and the ability to recognise candidate polyadenyla-
tion-acceptor sites will allow these aspects of protease biology
to be studied in greater depth.
7. Mutations and polymorphisms
Although mutations in individual protease loci that give rise
to clinical disease are the exception rather than the rule, the
distribution of these can be informative. Heamophilia B is a
good example where the e¡ects on protein domains and con-
trol regions within the factor IX serine protease locus have
provided insights into the subtleties of structure, function,
transcriptional regulation and phenotype [24]. No less than
689 unique molecular events have been detected in all regions
of the gene except the poly (A) site. The 425 di¡erent amino
acid substitutions are under-represented within the pre-pep-
tide and activation peptide regions and over-represented in
the calcium-binding EGF, and catalytic domains. The power
of combining the now almost complete genome mapping data
with family linkage studies is likely to reveal the molecular
basis for more monogenic diseases involving proteases.
Polymorphisms can include the same kind of molecular
events as mutations but at a higher population frequency
(above 1%). The recent genome-wide study of 1.4 million sin-
gle nucleotide polymorphisms (SNPs) shows the potential for
investigating associations with complex disease traits [25]. A
recent analysis of 24 kb from the ACE locus uncovered no
less than 78 varying sites that could be resolved into 13 dis-
tinct haplotypes, some of which may confer an increased sus-
ceptibility to cardiovascular disease [26]. Similar levels of pop-
Fig. 1. Genomic context and protein features for the HtrA1 and HtrA2 proteases. Panels (a) and (b) include selected genomic viewer features
on the left-hand side (background information, including additional display options, can be accessed at genome.cse.ucsc.edu/ and www.
ensembl.org/). For each of the genes in (a) and (b) the immediate (left-hand, irrespective of orientation) neighbouring gene is included. From
top to bottom, the features are; the base position, which refers to the coordinates in the golden path assembly, used by both the University of
Santa Cruz and Ensembl teams (the two panels are not to scale as (a) is a longer gene); the cytogenetic band is immediately underneath. The
blue lines are gene structures as con¢rmed by the consensus of the alignments between genomic and mRNAs. The brown lines are the con-
¢rmed gene models from Ensembl. The black numbers are mRNA primary accession numbers that have exon matches to the genomic DNA,
e.g. The HtrA1/PRSS11 has four mRNA entries and the HtrA2/Omi gene has ¢ve. Panel (b) shows two SNPs in exons of the AUP1 gene. Ex-
amination of the graphically depicted features for these genes and following the links back to database entries and publications reveals many
subtleties but only a few can be highlighted here. HrA1 and 2 are paralogues, sharing 45% amino acid identity across 320 residues, but both
their gene structures, orientations and neighbouring genes are di¡erent. HtrA1 shows two 5P exons, separated by large introns that are lacking
in HtrA2. Given that AF097709 is slightly shorter, the exons agree with D87256 and Y07921. AF070555, a partial sequence from infant brain,
shows exon 4 extended by seven bases but this clone does not translate into a complete protein. The more compact gene structure of HrA2 (b)
is in opposite orientation i.e. the longest exon (8) is on the 3P end. The gene structure is supported by ¢ve mRNAs but four of these show al-
ternative transcripts; AF18491 lacking exons 2 and 6, AF141306, loss of exon 2 plus an extended exon 4, and AF141306, the fusion between
exons 4 and 5. Unusually, the 3P end of AF143065 overlaps with the two 5P-most exons of the neighbouring AUP1 gene. Panels (c) and (d)
show the depiction of protein domains in HtrA1 and HtrA2. The graphical displays were retrieved from InterPro (www.ebi.ac.uk/interpro/).
The domain databases used within InterPro, listed on the left side, are; PS = PROSITE, PF = Pfam, SM = SMART, PR = PRINTS. Both gene
products are homologous to the C-terminal (3P end) of bacterial heat-shock proteases, a relationship detected within InterPro by the combina-
tion of a trypsin and PDZ domain as well as a match to the proteases 2C family pattern in PRINTS (this has since been re-classi¢ed as family
S1C in MEROPS) [12]. However, panel (c) shows that HtraA1 has two additional N-terminal features, the insulin growth factor-binding pro-
tein (IGFBP), and a Kazal protease inhibitor motif. These correspond to the three 5P most exons in the gene. The particular four-domain com-
bination in HrA1 is, so far, only detectable in mammals suggesting that the two N-terminal domains may have been ‘shu¥ed-in’ after duplica-
tion of a common ancestor. The combined utility of the annotated gene and protein features, in this example, is the ability to predict
accurately which protein domains in (d) might be a¡ected by the complex exon-splicing pattern observed in (b).
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ulation diversity (179 variants within 66 kb) have been re-
ported for calpain 10 [27]. Evidence suggests that certain hap-
lotype combinations for calpain 10 may a¡ect susceptibility to
type-2 diabetes in both Mexicans and Europeans although the
mechanism for such an a¡ect is not yet clear. Those SNPs
already mapped within protease loci will provide the molec-
ular data for disease association studies [28].
8. Drug targets
The number of human proteases reported to be under in-
vestigation as drug targets more than doubled between 1998
and 2000 and now represents approximately 15% of docu-
mented proteases [29,30]. The genome data will enable a com-
prehensive in silico evaluation of those sequences that are al-
ready being evaluated as therapeutic targets. However, many
of more recently cloned and genomically derived proteases are
‘orphans’ in the sense that their physiologically and/or patho-
logically relevant substrate(s) are unknown. Therefore, phar-
maceutical or biotechnology operations should consider the
industrialisation of both the expression of recombinant pro-
teins and screening for surrogate substrates derived from pep-
tide libraries. Such a characterisation pipeline could be priori-
tised by using bioinformatic ¢lters such as signal peptides and
degrees of similarity to paralogues that are already targets.
Subsequent high-throughput screening for inhibitors without
pre-existing target indications would be a speculative commit-
ment of resources. However, the production of tool inhibitors
and the consequent opportunity for accelerated target valida-
tion is a logical way to exploit the genome data for proteases.
9. Conclusions
By accepting a short time lag, the protease a¢cionado can
now be assured that any new sections of transcript or genomic
sequence with signi¢cant sequence similarity to a known pro-
tease will be incorporated into the secondary databases. They
then have access to an extensive range of annotated features
provided by genome viewers and protein domain databases. It
is certain that experimental work and homology searches of
genome data will continue to discover new proteases, possibly
with novel mechanisms, structures or domain combinations.
Numerically, however, the data suggest that the majority of
human proteases are already represented in transcript data.
The recent expansion of the protease collection in silico has
exacerbated the bottleneck for experimental characterisation.
It will be of interest to see which of the emerging technologies
for high-throughput biology will provide the necessary data
and expedite the conversion of orphan proteases into new
drug targets.
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